Grifols, S.A.
Records under this name other than the patents Grifols, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 49 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,482,679 | Composition for Use as an Abnormal Coagulation Control Plasma in in Vitro Assays Formerly held In force · High confidence | In force | High confidence | |
| US 7,511,818 | Apparatus for Measuring the Optical Absorbency of Samples of Liquids, Method and Reaction Container for Its Implementation Term ended Term ended Nov 2, 2026 · High confidence | Term ended | Term ended Nov 2, 2026 | High confidence |
| US 9,844,548 | Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals Lapsed on the fee record Ended Dec 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 19, 2025 | From the USPTO record |
| US 9,376,674 | Process to prepare a stable thrombin composition Term ended Term ended Oct 13, 2025 · From the USPTO record | Term ended | Term ended Oct 13, 2025 | From the USPTO record |
| US 7,291,595 | Use of ALPHA-1 Antitrypsin for the Preparation of Medicaments for the Treatment of Fibromyalgia Term ended Term ended Sep 19, 2025 · High confidence | Term ended | Term ended Sep 19, 2025 | High confidence |
| US 11,116,765 | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria Lapsed on the fee record Ended Sep 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 14, 2025 | From the USPTO record |
| US 7,332,577 | Therapeutic Human Albumin Solutions with Low Prekallikrein Activator (PKA) Activity and Process for Obtaining Them Term ended Term ended Jul 19, 2025 · High confidence | Term ended | Term ended Jul 19, 2025 | High confidence |
| US 11,026,941 | Concentrated, inhalable ciprofloxacin formulation Lapsed on the fee record Ended Jun 8, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 8, 2025 | From the USPTO record |
| US 8,414,915 | Dual action, inhaled formulations providing both an immediate and sustained release profile Lapsed on the fee record Ended Apr 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 9, 2025 | From the USPTO record |
| US 9,545,401 | Concentrated, inhalable ciprofloxacin formulation Lapsed on the fee record Ended Jan 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2025 | From the USPTO record |